Heparin-induced thrombocytopenia risk factors: Difference between revisions
No edit summary |
|||
| Line 2: | Line 2: | ||
{{CMG}}; '''Associate Editor-In-Chief:''' {{CZ}}, Aric C. Hall, M.D., [mailto:achall@bidmc.harvard.edu] | {{CMG}}; '''Associate Editor-In-Chief:''' {{CZ}}, Aric C. Hall, M.D., [mailto:achall@bidmc.harvard.edu] | ||
==Overview== | ==Overview== | ||
[[Heparin-induced thrombocytopenia]] is diagnosed when the [[platelet]] count falls by > 50% typically after 5-10 days of [[heparin]] therapy. | [[Heparin-induced thrombocytopenia]] is diagnosed when the [[platelet]] count falls by > 50% typically after 5-10 days of [[heparin]] therapy. Increased risks for [[heparin-induced thrombocytopenia]] depends on type of heparin ([[unfractionated heparin]] > [[low molecular weight heparin]]), duration of therapy, females and type of patients (commoner in surgical patients that require large amount of heparin) | ||
==Risk factors== | ==Risk factors== | ||
* Genetic risk factors for thrombosis such as [[factor V Leiden]], [[prothrombin]] gene mutation, [[methylenetetrahydrofolate reductase]] ([[MTHFR]]) polymorphism and platelet-receptor polymorphisms do not increase the risk of developing HIT associated thrombosis. | * Genetic risk factors for thrombosis such as [[factor V Leiden]], [[prothrombin]] gene mutation, [[methylenetetrahydrofolate reductase]] ([[MTHFR]]) polymorphism and platelet-receptor polymorphisms do not increase the risk of developing HIT associated thrombosis. | ||
* Factors that affect the risk of developing HIT are noted as follows.<ref>Warkentin TE, Sheppard JA, Sigouin CS, Kohlmann T, Eichler P, Greinacher A. Gender imbalance and risk factor interactions in heparin-induced thrombocytopenia. ''Blood'' 2006;108:2937-41. PMID 16857993.</ref> | * Factors that affect the risk of developing HIT are noted as follows.<ref>Warkentin TE, Sheppard JA, Sigouin CS, Kohlmann T, Eichler P, Greinacher A. Gender imbalance and risk factor interactions in heparin-induced thrombocytopenia. ''Blood'' 2006;108:2937-41. PMID 16857993.</ref> | ||
Revision as of 17:20, 10 December 2011
|
Heparin-induced thrombocytopenia |
|
Differentiating Heparin-induced thrombocytopenia from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Heparin-induced thrombocytopenia risk factors On the Web |
|
American Roentgen Ray Society Images of Heparin-induced thrombocytopenia risk factors |
|
Directions to Hospitals Treating Heparin-induced thrombocytopenia |
|
Risk calculators and risk factors for Heparin-induced thrombocytopenia risk factors |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor-In-Chief: Cafer Zorkun, M.D., Ph.D. [2], Aric C. Hall, M.D., [3]
Overview
Heparin-induced thrombocytopenia is diagnosed when the platelet count falls by > 50% typically after 5-10 days of heparin therapy. Increased risks for heparin-induced thrombocytopenia depends on type of heparin (unfractionated heparin > low molecular weight heparin), duration of therapy, females and type of patients (commoner in surgical patients that require large amount of heparin)
Risk factors
- Genetic risk factors for thrombosis such as factor V Leiden, prothrombin gene mutation, methylenetetrahydrofolate reductase (MTHFR) polymorphism and platelet-receptor polymorphisms do not increase the risk of developing HIT associated thrombosis.
- Factors that affect the risk of developing HIT are noted as follows.[1]
- Duration of heparin treatment; long duration, up to 2 weeks is associated with the greatest risk.
- The type of heparin involved; unfractionated heparinUFH has a greater risk than low molecular weight heparin LMWH.
- The type of patient; surgical patients are at higher risk than medical; cardiac surgical patients have the highest risk of all.
- Females have a higher risk.
Reference
- ↑ Warkentin TE, Sheppard JA, Sigouin CS, Kohlmann T, Eichler P, Greinacher A. Gender imbalance and risk factor interactions in heparin-induced thrombocytopenia. Blood 2006;108:2937-41. PMID 16857993.